Research programme: adoptive T-cell therapies - Eutilex

Drug Profile

Research programme: adoptive T-cell therapies - Eutilex

Alternative Names: CTAG1B-induced natural T cell therapy - Eutilex; HPV 4-1BB CTL - Eutilex; HPV-induced adoptive T cell therapy - Eutilex; HPViNT - Eutilex; Human pappilomavirus-induced natural T cell therapy - Eutilex; Mesothelin 4-1BB CTL - Eutilex; Mesothelin-induced adoptive T cell therapy - Eutilex; Mesothelin-induced natural T cell therapy - Eutilex; MesotheliniNT - Eutilex; New York oesophageal squamous cell carcinoma-1 antigen-induced natural T cell therapy - Eutilex; NY-ESO1-induced adoptive T cell therapy - Eutilex; NYESOiNT - Eutilex; NYESOiNT 4-1BB CTL - Eutilex

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eutilex
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Nov 2017 Preclinical trials in Cancer in South Korea (Parenteral) before November 2017 (Eutilex pipeline, November 2017)
  • 06 Nov 2017 Eutilex files an IND application for NY-ESO1-induced adoptive T cell therapy and Mesothelin-induced adoptive T cell therapy in Cancer before November 2017 (Eutilex website, November 2017)
  • 06 Nov 2017 Eutilex plans phase I trials for NY-ESO1-induced adoptive T cell therapy and Mesothelin-induced adoptive T cell therapy in Cancer (Eutilex website, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top